Ventilator-associated pneumonia caused by OXA-48-producing Escherichia coli complicated by ciprofloxacin-associated rhabdomyolysis

J Infect Chemother. 2013 Dec;19(6):1214-7. doi: 10.1007/s10156-013-0628-3. Epub 2013 Jun 7.

Abstract

We report the emergence of OXA-48 carbapenemase-producing Escherichia coli in Austria causing ventilator-associated pneumonia in a traveler returning from Egypt. Depending on resistance testing, quinolones may remain a therapeutic option for infections caused by these multiple resistant pathogens, as this class of drugs has a favorable safety and tolerability profile when compared to the alternatives. In this patient, however, the clinical course was dramatically complicated by the development of ciprofloxacin-associated rhabdomyolysis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use
  • Ciprofloxacin / adverse effects*
  • Ciprofloxacin / therapeutic use
  • Escherichia coli / isolation & purification*
  • Escherichia coli Infections / etiology*
  • Escherichia coli Infections / microbiology
  • Escherichia coli Proteins
  • Humans
  • Male
  • Middle Aged
  • Pneumonia, Ventilator-Associated / microbiology*
  • Rhabdomyolysis / chemically induced*
  • Rhabdomyolysis / microbiology*
  • beta-Lactamases

Substances

  • Anti-Bacterial Agents
  • Escherichia coli Proteins
  • Ciprofloxacin
  • beta-Lactamases